NSE / BSEHealthcare
β‚Ή942.40+0.15+0.02%
P/E66.2Mkt Capβ‚Ή35.38 K CrEV/EBITDA61.4

Anthem Biosciences Limited

P/E66.2Mkt Capβ‚Ή35.38 K CrEV/EBITDA61.4
Company Profile

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Strong 5-year revenue CAGR of 17.5%

Concerns1

  • Negative free cash flow (β‚Ή159 Cr)

Rule-based from financial data. Not advice.

Price Historyβ–² 12.90% over 1Y

Monthly Returns

Unlock Monthly Returns

Available on Pro and Institutional plans.

Sign up free

Year-to-Date ROI

Unlock Year-to-Date ROI

Available on Pro and Institutional plans.

Sign up free

Historical Volatility

Unlock Historical Volatility

Available on Pro and Institutional plans.

Sign up free

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.84 K Crβ–² 29.8%
EBITDA Growthβ€”
Net Profitβ‚Ή506.00 Crβ–² 34.9%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 179.9%
Revenue CAGR 5Y17.5%
EBITDA CAGR 5Y23.1%
Net Profit CAGR 5Y32.2%
NP Growth 1Y34.9%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 7 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.84 K Crβ€”β‚Ή506.00 Crβ€”β€”20.5%29.8%34.9%
Mar 2024β‚Ή1.42 K Crβ€”β‚Ή375.00 Crβ€”β€”19.4%34.2%-2.8%
Mar 2023β‚Ή1.06 K Crβ€”β‚Ή386.00 Crβ€”β€”22.2%-14.1%-4.9%
Mar 2022β‚Ή1.23 K Crβ€”β‚Ή406.00 Crβ€”β€”29.9%11.6%49.8%
Mar 2021β‚Ή1.10 K Crβ€”β‚Ή271.00 Crβ€”β€”38.7%74.2%191.4%
Mar 2020β‚Ή633.00 Crβ€”β‚Ή93.00 Crβ€”β€”22.1%1.1%20.8%
Mar 2019β‚Ή626.00 Crβ€”β‚Ή77.00 Crβ€”β€”23.3%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Free plan Β· showing 1 year of data.Upgrade

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2025
Revenue / Net Sales1,841
Total Expenses1,151
EBIT / Operating Profit690
OPM %37%
Other Income109
Finance Costs9
Depreciation & Amortisation78
Profit Before Tax711
Tax %29%
Net Profit / PAT506
EPS (β‚Ή)9.05
Dividend Payout %0%

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Anthem Biosciences Limitedthis co.β‚Ή35.38 K Crβ‚Ή1.84 K Cr66.2012.4061.4029.8%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Anthem Biosciences Limited and the metrics that matter.

Browse the full Equiscale Academy